Comparison of Clinical Efficacy between a Single Administration of Long-Acting Gonadotrophin-Releasing Hormone Agonist (GnRHa) and Daily Administrations of Short-Acting GnRHa in In Vitro Fertilization-Embryo Transfer Cycles

Abstract

This study was aimed to evaluate the efficacy of a single administration of long-acting gonadotrophin-releasing hormone agonist (GnRHa) as compared with daily administrations of short-acting GnRHa in controlled ovarian hyperstimulation (COH) for in vitro fertilization and embryo transfer (IVF-ET) cycles. The mean dosage of recombinant follicle-stimulating hormone (rFSH) required for COH (2,354.5±244.2 vs. 2,012.5±626.1 IU) and the rFSH dosage per retrieved oocyte (336.7±230.4 vs. 292.1±540.4 IU) were significantly higher in the long-acting GnRHa group (N=22) than those in the short-acting GnRHa group (N=28) (p<0.05). However, the mean number of visit to the hospital that was required before ovum pick-up (3.3±0.5 vs. 22.2±2.0) and the frequency of injecting GnRHa and rFSH (12.8±1.2 vs. 33.5±3.5) were significantly decreased in the long-acting GnRHa group (p<0.0001). The clinical pregnancy rate, implantation rate, and early pregnancy loss rate were not significantly different between the 2 groups. So, we suggest that a single administration of long-acting GnRHa is a useful alternative for improving patient's convenience with clinical outcomes comparable to daily administrations of short-acting GnRHa in COH for IVF-ET cycles.

Self‐control study on reduced‐dose depot versus daily administration of gonadotrophin‐releasing hormone agonists for pituitary desensitization in in vitro fertilization cycles

“…Although the number of days of administration and dose of HMG in the LA group were significantly higher than those in the SA group, the serum E 2 level on the day of hCG administration was significantly higher in the SA group. These results are in accordance with previous reports …”

Prolonged pituitary down-regulation with full-dose of gonadotropin-releasing hormone agonist in different menstrual cycles: a retrospective cohort study

“…It has been noted that clinical pregnancy rate might increase when patients are given a period of artificial amenorrhea caused by GnRH-a (Cai et al, 2018; Liao et al, 2015; Martínez et al, 2014; Ren et al, 2014). One full-dose depot of long-acting GnRH-a per COH cycle would be more convenient for women than short-acting GnRH-a injections because there are fewer injections, leading to greater compliance as well as fewer incidences of infection (Cheon et al, 2008; Gao et al, 2014).…”

Peer Review #4 of "Prolonged pituitary down-regulation with full-dose of gonadotropin-releasing hormone agonist in different menstrual cycles: a retrospective cohort study (v0.3)"

“…It has been noted that clinical pregnancy rate 62 might increase when patients are given a period of artificial amenorrhea caused by GnRH-a [Cai, 63 et al, 2018;Liao et al, 2015; Martínez et al, 2014;Ren et al, 2014]. One full-dose depot of 64 long-acting GnRH-a per COH cycle would be more convenient for women than short-acting 65 GnRH-a injections because there are fewer injections, leading to greater compliance as well as 66 fewer incidences of infection [Cheon et al, 2008;Gao et al, 2014].…”

“…It has been noted that clinical pregnancy rate 62 might increase when patients are given a period of artificial amenorrhea caused by GnRH-a [Cai, 63 et al, 2018;Liao et al, 2015; Martínez et al, 2014;Ren et al, 2014]. One full-dose depot of 64 long-acting GnRH-a per COH cycle would be more convenient for women than short-acting 65 GnRH-a injections because there are fewer injections, leading to greater compliance as well as 66 fewer incidences of infection [Cheon et al, 2008;Gao et al, 2014].67 Liao et al reported that clinical pregnancy rates in patients who received a depot GnRHa 68 regimen was higher than that of the daily low-dose group (57.5% vs. 46.9%) [Liao et al, 2015]. 69 The prolonged regimen can be divided into two different types, according to the time that the 70 GnRH agonist is administered.…”